Rivaroxaban Initiation Timing and Clinical Outcomes After Acute Ischemic Stroke in Patients with Non-Valvular Atrial Fibrillation: An IPTW-Based Cohort Study
Clinical and Applied Thrombosis/Hemostasis · 2026-01 · 32
DOI: 10.1177/10760296261429254 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, online erschienen am 02.03.2026. Verfasst von Jia Hu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Nanjing Drum Tower Hospital, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangs…. Hauptthemen laut MEDLINE: Rivaroxaban, Atrial Fibrillation, Ischemic Stroke, Factor Xa Inhibitors. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University, Project of China Hospital Reform and Development Research and Development Research Institute, Nanjing University, Aid project of Nanjing Drum Tower Hospital Health, Education & Research Foundation.
Themen: Schlaganfall
Abstract (Originalsprache)
Background
The optimal timing of anticoagulation initiation after acute ischemic stroke (AIS) in patients with non-valvular atrial fibrillation (NVAF) remains uncertain. We evaluated the association between early versus delayed rivaroxaban initiation and clinical outcomes in this population.
Methods
In this retrospective, single-center cohort study, 401 hospitalized AIS patients with NVAF receiving rivaroxaban between January 2019 and June 2024 were classified into early (≤7 days) or delayed (>7 days) initiation groups. Primary outcomes were excellent [modified Rankin Scale (mRS) 0-1] and good (mRS 0-2) functional outcomes at 90 days and 12 months. Secondary outcomes included recurrent ischemic stroke, clinically relevant major bleeding, all-cause mortality, composite outcomes, and in-hospital length of stay (LOS). Inverse probability of treatment weighting (IPTW) was applied, followed by regression analyses. Sensitivity and subgroup analyses were performed.
Results
After IPTW adjustment, early rivaroxaban initiation was associated with a higher likelihood of achieving mRS 0-1 at 90 days (aOR 1.76, 95% CI 1.02-3.05) and 12 months (aOR 1.82, 95% CI 1.08-3.06), as well as a shorter LOS. No significant differences were observed for mRS 0-2 or other secondary outcomes. Sensitivity analyses yielded consistent results, and subgroup analyses suggested a trend toward greater benefit among patients with higher baseline stroke severity (NIHSS >7).
Conclusion
Early rivaroxaban initiation after AIS in patients with NVAF was associated with improved excellent functional outcomes without an apparent increase in adverse events, supporting its potential feasibility in routine practice and warrant confirmation in larger prospective studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Nanjing Drum Tower Hospital, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China.
- School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China.
- Department of Pharmacy, The First People's Hospital of Changzhou, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
- Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
- Department of Pharmacy, the Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, Jiangsu, China.
ORCID-Profile: Jia Hu, Peng Xia, Jialin Zhang, Xiaodi Yan, Weihong Ge, Chenxiao Jiang
Förderung
- the Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University
- Project of China Hospital Reform and Development Research and Development Research Institute, Nanjing University
- Aid project of Nanjing Drum Tower Hospital Health, Education & Research Foundation
Zitieren
APA
Hu, J., Xia, P., Zhang, J., Yan, X., Ge, W., & Jiang, C. (2026). Rivaroxaban Initiation Timing and Clinical Outcomes After Acute Ischemic Stroke in Patients with Non-Valvular Atrial Fibrillation: An IPTW-Based Cohort Study. Clinical and Applied Thrombosis/Hemostasis, 32. https://doi.org/10.1177/10760296261429254
Vancouver
Hu J, Xia P, Zhang J, Yan X, Ge W, Jiang C. Rivaroxaban Initiation Timing and Clinical Outcomes After Acute Ischemic Stroke in Patients with Non-Valvular Atrial Fibrillation: An IPTW-Based Cohort Study. Clinical and Applied Thrombosis/Hemostasis. 2026;32. doi:10.1177/10760296261429254
BibTeX
@article{Hu2026,
author = {Hu, Jia and Xia, Peng and Zhang, Jialin and Yan, Xiaodi and Ge, Weihong and Jiang, Chenxiao},
title = {Rivaroxaban Initiation Timing and Clinical Outcomes After Acute Ischemic Stroke in Patients with Non-Valvular Atrial Fibrillation: An IPTW-Based Cohort Study},
journal = {Clinical and Applied Thrombosis/Hemostasis},
year = {2026},
volume = {32},
doi = {10.1177/10760296261429254}
}
EUVIMED